FDA Advisory Committee Decides Review Date for Mesoblast’s Remestemcel-L

  • Jul 21, 2020 AEST
  • Team Kalkine

Mesoblast Limited (ASX:MSB) said that the Oncologic Drugs Advisory Committee of the US FDA had scheduled a meeting on 13 August 2020 for the review of data supporting MSB’s Biologics License Application for approval of RYONCIL™ (remestemcel-L) for the treatment of SR-aGVHD in children.

Moreover, RYONCIL is under Priority Review by the FDA with an action date of 30 September 2020, under the Prescription Drug User Fee Act.

Post announcement, MSB quoted at A$3.610 up by 7.761% at AEST 12:01 PM.


The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


Penny stocks have been known to attract investors who are looking for explosive gains and it is possible to get lucky with these typically speculative investments. Just as the name suggests, penny stocks trade at low prices and are common shares of small public companies.

Get an exclusive insight into the features of penny stocks along with their pros and cons. Read about what you should be wary about when figuring out ways to invest in them, so that the possibility for big rewards does not tend to outweigh the risks.

Find out more about penny stock winners from 2019

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK